<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03008096</url>
  </required_header>
  <id_info>
    <org_study_id>LSG-BTC-LVAD</org_study_id>
    <nct_id>NCT03008096</nct_id>
  </id_info>
  <brief_title>Laparoscopic Sleeve Gastrectomy as Bridge-to-Candidacy for Obese Left-Ventricular Assist Device Patients</brief_title>
  <acronym>LSG-BTC-LVAD</acronym>
  <official_title>Laparoscopic Sleeve Gastrectomy as Bridge-to-Candidacy for Obese Left-Ventricular Assist Device Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipp Angleitner</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In LVAD (Left-Ventricular Assist Device) patients, evidence is lacking regarding the safety&#xD;
      and efficacy of Laparoscopic Sleeve Gastrectomy (LSG) as a means to reach a Body Mass Index&#xD;
      (BMI) within listing criteria for heart transplantation. To our knowledge, this is the first&#xD;
      prospective study to evaluate laparoscopic sleeve gastrectomy in LVAD patients as&#xD;
      bridge-to-candidacy for heart transplantation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Continuous-flow left-ventricular assist devices are increasingly used for the treatment of&#xD;
      acute or chronic end-stage heart failure (Mancini 2015). Three main implantation strategies&#xD;
      exist: destination therapy (support until end of life), bridge to transplantation (support&#xD;
      until transplantation), and bridge to candidacy (support until transplantation criteria are&#xD;
      met). Although LVAD support delivers excellent short-term and long-term results, the current&#xD;
      gold standard and last resort of treatment for end-stage heart failure remains orthotopic&#xD;
      heart transplantation (Lund 2015).&#xD;
&#xD;
      Obesity increases mortality in heart transplantat recipients and therefore is included in the&#xD;
      2006 transplantation criteria. The heart transplant program of the Medical University of&#xD;
      Vienna uses a BMI of 30 kg/m2 as the upper limit to be listed for heart transplantation&#xD;
      (Mehra 2016).&#xD;
&#xD;
      Ambulatory patients on CF-LVAD support have a tendency to gain weight because of reduced&#xD;
      physical fitness, inability to work, and genetic predisposition. In many cases, binge eating&#xD;
      is used as a coping mechanism to alleviate depression and anxiety associated with heart&#xD;
      failure and LVAD therapy.&#xD;
&#xD;
      Conservative measures to reduce weight and increase physical fitness fail in many patients.&#xD;
      As a result, in many cases these patients remain ineligible for heart transplantation for&#xD;
      months or years. For the entire period of ineligibility, they are subject to the constant&#xD;
      life-threatening risks of LVAD treatment, most importantly ischemic and hemorrhagic stroke,&#xD;
      pump thrombosis, infection, right heart failure, and bleeding episodes in the&#xD;
      gastrointestinal tract or other organ systems (Kirklin 2015).&#xD;
&#xD;
      Bariatric surgery has been shown to be superior to conservative measures of weight reduction&#xD;
      in morbidly obese patients. Laparoscopic sleeve gastrectomy, one of the most commonly&#xD;
      employed bariatric procedures, reduces body weight by a non-malabsorptive mechanism (Colquitt&#xD;
      2014). Gastric volume reduction is achieved by resection along the stomach's greater&#xD;
      curvature and creation of a gastric tube, leading to reduced capacity for ingested food,&#xD;
      decreased appetite and earlier satiety. In contrast to malabsorptive bariatric procedures,&#xD;
      resorption and efficacy of immunosuppressive drugs, an inevitable feature of post-transplant&#xD;
      therapy, are only minimally influenced following sleeve gastrectomy. Furthermore, there is&#xD;
      less requirement for substitution of trace elements and vitamins, for example Vitamin B12.&#xD;
      Due to the fact that the majority of obese LVAD patients are within a BMI range of 30 to 40&#xD;
      kg/m2, the moderate weight loss achieved by sleeve gastrectomy is expected to be sufficient&#xD;
      for reaching the eligibility criterion for heart transplantation.&#xD;
&#xD;
      It is unclear, whether laparoscopic sleeve gastrectomy is effective and safe in patients on&#xD;
      CF-LVAD. The literature is limited to case reports and retrospective series of up to 4&#xD;
      patients. This is the first prospective series including more than 4 patients with the&#xD;
      specific aim to enable obese LVAD supported patients to reach a BMI within listing criteria&#xD;
      for heart transplantation by the means of laparoscopic sleeve gastrectomy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BMI (Body-Mass-Index)</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patient weight is measured and BMI is calculated at the time of LSG and at 3, 6, and 12 months post-LSG. The rate of patients with successful weight reduction to a BMI lower than 30kg/m2 is calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>NYHA (New York Heart Association) Class</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients' NYHA Class (I, II, IIIa, IIIb, IV) is assessed pre-operatively and at 3, 6, and 12 months post-LSG and changes are noted.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-min Walking Test</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients are performing the 6-min walking test pre-operatively and at 3, 6, and 12 months post-LSG and changes of the distance walked (m) are assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D (EuroQol five dimensions) questionnaire</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients are undertaking the EQ-5D quality-of-life questionnaire (mobility, self care, usual activities, pain/discomfort, anxiety/depression, and visual analog scale) pre-operatively and at 3, 6, and 12 months post-LSG to assess changes in the post-operative quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Ability questionnaire</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients are undertaking the Work Ability questionnaire including questions about their current or former occupation pre-operatively and at 3, 6, and 12 months post-LSG to assess changes in occupational issues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHOQOL-BREF (World Health Organization Quality of Life) questionnaire</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients are undertaking the WHOQOL-BREF questionnaire including questions regarding their quality of life pre-operatively and at 3, 6, and 12 months post-LSG to assess changes regarding social, emotional, and health-related issues.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LVEF (Left-Ventricular Ejection Fraction)</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>LVEF (%) is going to be measured by echocardiography pre-operatively and at 3, 6, and 12 months post-LSG to investigate changes of cardiac function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VO2 max (maximum rate of oxygen consumption)</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Patients are undergoing spiroergometry pre-operatively and at 3, 6, and 12 months post-LSG to investigate changes of cardiac performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse events</measure>
    <time_frame>12 months post-LSG</time_frame>
    <description>Adverse and severe adverse events including death, unplanned hospital readmission, reoperation, major bleeding, cardiac arrhythmia, pericardial fluid collection, device malfunction, hemolysis, hepatic dysfunction, hypertension, major infection, myocardial infarction, neurological dysfunction, psychiatric episodes, renal dysfunction, respiratory failure, right heart failure, arterial non-CNS (central nervous system) thromboembolism, venous thromboembolism, wound dehiscence, gastroesophageal reflux disease, vomiting, gastric anastomotic leak, trocar site infection, trocar site hernia, gastric pouch dilation, and others are assessed in the immediately post-operative phase and at 3, 6, and 12 months post-LSG.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heart Failure</condition>
  <condition>Obesity</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic Sleeve Gastrectomy</intervention_name>
    <description>Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.</description>
    <other_name>Bariatric Surgery</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ambulatory patients on LVAD-support for end-stage heart failure&#xD;
&#xD;
          -  Bridge-to-Candidacy strategy&#xD;
&#xD;
          -  BMI &gt; 35kg/m2&#xD;
&#xD;
          -  Failure to reach BMI &lt; 30kg/m2 with conservative measures&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Ability to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Absolute contraindications to subsequent heart transplantation other than obesity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Zimpfer, Priv.-Doz. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp Angleitner, Dr.</last_name>
    <phone>+4314040052620</phone>
    <email>philipp.angleitner@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Zimpfer, Priv.-Doz. Dr.</last_name>
    <phone>+4314040052620</phone>
    <email>daniel.zimpfer@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Cardiac Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Angleitner, Dr.</last_name>
      <phone>+4314040052620</phone>
      <email>philipp.angleitner@meduniwien.ac.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Mancini D, Colombo PC. Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant. J Am Coll Cardiol. 2015 Jun 16;65(23):2542-55. doi: 10.1016/j.jacc.2015.04.039.</citation>
    <PMID>26065994</PMID>
  </reference>
  <reference>
    <citation>Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015 Oct;34(10):1244-54. doi: 10.1016/j.healun.2015.08.003. Epub 2015 Aug 28. No abstract available.</citation>
    <PMID>26454738</PMID>
  </reference>
  <reference>
    <citation>Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1-23. doi: 10.1016/j.healun.2015.10.023. No abstract available.</citation>
    <PMID>26776864</PMID>
  </reference>
  <reference>
    <citation>Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015 Dec;34(12):1495-504. doi: 10.1016/j.healun.2015.10.003. Epub 2015 Oct 8.</citation>
    <PMID>26520247</PMID>
  </reference>
  <reference>
    <citation>Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014 Aug 8;2014(8):CD003641. doi: 10.1002/14651858.CD003641.pub4.</citation>
    <PMID>25105982</PMID>
  </reference>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 16, 2016</study_first_submitted>
  <study_first_submitted_qc>December 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2017</study_first_posted>
  <last_update_submitted>December 29, 2016</last_update_submitted>
  <last_update_submitted_qc>December 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Philipp Angleitner</investigator_full_name>
    <investigator_title>Resident</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03008096
org study id: LSG-BTC-LVAD
nct id: NCT03008096
lead sponsor: 
has dmc: No
In LVAD (Left-Ventricular Assist Device) patients, evidence is lacking regarding the safety
      and efficacy of Laparoscopic Sleeve Gastrectomy (LSG) as a means to reach a Body Mass Index
      (BMI) within listing criteria for heart transplantation. To our knowledge, this is the first
      prospective study to evaluate laparoscopic sleeve gastrectomy in LVAD patients as
      bridge-to-candidacy for heart transplantation.
Continuous-flow left-ventricular assist devices are increasingly used for the treatment of
      acute or chronic end-stage heart failure (Mancini 2015). Three main implantation strategies
      exist: destination therapy (support until end of life), bridge to transplantation (support
      until transplantation), and bridge to candidacy (support until transplantation criteria are
      met). Although LVAD support delivers excellent short-term and long-term results, the current
      gold standard and last resort of treatment for end-stage heart failure remains orthotopic
      heart transplantation (Lund 2015).

      Obesity increases mortality in heart transplantat recipients and therefore is included in the
      2006 transplantation criteria. The heart transplant program of the Medical University of
      Vienna uses a BMI of 30 kg/m2 as the upper limit to be listed for heart transplantation
      (Mehra 2016).

      Ambulatory patients on CF-LVAD support have a tendency to gain weight because of reduced
      physical fitness, inability to work, and genetic predisposition. In many cases, binge eating
      is used as a coping mechanism to alleviate depression and anxiety associated with heart
      failure and LVAD therapy.

      Conservative measures to reduce weight and increase physical fitness fail in many patients.
      As a result, in many cases these patients remain ineligible for heart transplantation for
      months or years. For the entire period of ineligibility, they are subject to the constant
      life-threatening risks of LVAD treatment, most importantly ischemic and hemorrhagic stroke,
      pump thrombosis, infection, right heart failure, and bleeding episodes in the
      gastrointestinal tract or other organ systems (Kirklin 2015).

      Bariatric surgery has been shown to be superior to conservative measures of weight reduction
      in morbidly obese patients. Laparoscopic sleeve gastrectomy, one of the most commonly
      employed bariatric procedures, reduces body weight by a non-malabsorptive mechanism (Colquitt
      2014). Gastric volume reduction is achieved by resection along the stomach's greater
      curvature and creation of a gastric tube, leading to reduced capacity for ingested food,
      decreased appetite and earlier satiety. In contrast to malabsorptive bariatric procedures,
      resorption and efficacy of immunosuppressive drugs, an inevitable feature of post-transplant
      therapy, are only minimally influenced following sleeve gastrectomy. Furthermore, there is
      less requirement for substitution of trace elements and vitamins, for example Vitamin B12.
      Due to the fact that the majority of obese LVAD patients are within a BMI range of 30 to 40
      kg/m2, the moderate weight loss achieved by sleeve gastrectomy is expected to be sufficient
      for reaching the eligibility criterion for heart transplantation.

      It is unclear, whether laparoscopic sleeve gastrectomy is effective and safe in patients on
      CF-LVAD. The literature is limited to case reports and retrospective series of up to 4
      patients. This is the first prospective series including more than 4 patients with the
      specific aim to enable obese LVAD supported patients to reach a BMI within listing criteria
      for heart transplantation by the means of laparoscopic sleeve gastrectomy.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: BMI (Body-Mass-Index)
time frame: 12 months post-LSG
description: Patient weight is measured and BMI is calculated at the time of LSG and at 3, 6, and 12 months post-LSG. The rate of patients with successful weight reduction to a BMI lower than 30kg/m2 is calculated.
measure: NYHA (New York Heart Association) Class
time frame: 12 months post-LSG
description: Patients' NYHA Class (I, II, IIIa, IIIb, IV) is assessed pre-operatively and at 3, 6, and 12 months post-LSG and changes are noted.
measure: 6-min Walking Test
time frame: 12 months post-LSG
description: Patients are performing the 6-min walking test pre-operatively and at 3, 6, and 12 months post-LSG and changes of the distance walked (m) are assessed.
measure: EQ-5D (EuroQol five dimensions) questionnaire
time frame: 12 months post-LSG
description: Patients are undertaking the EQ-5D quality-of-life questionnaire (mobility, self care, usual activities, pain/discomfort, anxiety/depression, and visual analog scale) pre-operatively and at 3, 6, and 12 months post-LSG to assess changes in the post-operative quality of life.
measure: Work Ability questionnaire
time frame: 12 months post-LSG
description: Patients are undertaking the Work Ability questionnaire including questions about their current or former occupation pre-operatively and at 3, 6, and 12 months post-LSG to assess changes in occupational issues.
measure: WHOQOL-BREF (World Health Organization Quality of Life) questionnaire
time frame: 12 months post-LSG
description: Patients are undertaking the WHOQOL-BREF questionnaire including questions regarding their quality of life pre-operatively and at 3, 6, and 12 months post-LSG to assess changes regarding social, emotional, and health-related issues.
measure: LVEF (Left-Ventricular Ejection Fraction)
time frame: 12 months post-LSG
description: LVEF (%) is going to be measured by echocardiography pre-operatively and at 3, 6, and 12 months post-LSG to investigate changes of cardiac function.
measure: VO2 max (maximum rate of oxygen consumption)
time frame: 12 months post-LSG
description: Patients are undergoing spiroergometry pre-operatively and at 3, 6, and 12 months post-LSG to investigate changes of cardiac performance.
measure: Severe adverse events
time frame: 12 months post-LSG
description: Adverse and severe adverse events including death, unplanned hospital readmission, reoperation, major bleeding, cardiac arrhythmia, pericardial fluid collection, device malfunction, hemolysis, hepatic dysfunction, hypertension, major infection, myocardial infarction, neurological dysfunction, psychiatric episodes, renal dysfunction, respiratory failure, right heart failure, arterial non-CNS (central nervous system) thromboembolism, venous thromboembolism, wound dehiscence, gastroesophageal reflux disease, vomiting, gastric anastomotic leak, trocar site infection, trocar site hernia, gastric pouch dilation, and others are assessed in the immediately post-operative phase and at 3, 6, and 12 months post-LSG.
intervention type: Procedure
intervention name: Laparoscopic Sleeve Gastrectomy
description: Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
other name: Bariatric Surgery
criteria: 
gender: All
minimum age: 18 Years
maximum age: 70 Years
healthy volunteers: No
last name: Daniel Zimpfer, Priv.-Doz. Dr.
role: Principal Investigator
affiliation: Medical University of Vienna
last name: Philipp Angleitner, Dr.
phone: +4314040052620
email: philipp.angleitner@meduniwien.ac.at
last name: Daniel Zimpfer, Priv.-Doz. Dr.
phone: +4314040052620
email: daniel.zimpfer@meduniwien.ac.at
facility: 
status: Recruiting
contact: 
country: Austria
citation: Mancini D, Colombo PC. Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant. J Am Coll Cardiol. 2015 Jun 16;65(23):2542-55. doi: 10.1016/j.jacc.2015.04.039.
PMID: 26065994
citation: Lund LH, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb S, Levvey BJ, Meiser B, Rossano JW, Yusen RD, Stehlik J. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Heart Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant. 2015 Oct;34(10):1244-54. doi: 10.1016/j.healun.2015.08.003. Epub 2015 Aug 28. No abstract available.
PMID: 26454738
citation: Mehra MR, Canter CE, Hannan MM, Semigran MJ, Uber PA, Baran DA, Danziger-Isakov L, Kirklin JK, Kirk R, Kushwaha SS, Lund LH, Potena L, Ross HJ, Taylor DO, Verschuuren EAM, Zuckermann A; International Society for Heart Lung Transplantation (ISHLT) Infectious Diseases, Pediatric and Heart Failure and Transplantation Councils. The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update. J Heart Lung Transplant. 2016 Jan;35(1):1-23. doi: 10.1016/j.healun.2015.10.023. No abstract available.
PMID: 26776864
citation: Kirklin JK, Naftel DC, Pagani FD, Kormos RL, Stevenson LW, Blume ED, Myers SL, Miller MA, Baldwin JT, Young JB. Seventh INTERMACS annual report: 15,000 patients and counting. J Heart Lung Transplant. 2015 Dec;34(12):1495-504. doi: 10.1016/j.healun.2015.10.003. Epub 2015 Oct 8.
PMID: 26520247
citation: Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight loss in adults. Cochrane Database Syst Rev. 2014 Aug 8;2014(8):CD003641. doi: 10.1002/14651858.CD003641.pub4.
PMID: 25105982
responsible party type: Sponsor-Investigator
investigator affiliation: Medical University of Vienna
investigator full name: Philipp Angleitner
investigator title: Resident
mesh term: Heart Failure
sharing ipd: No